A survey of United States rheumatologists concerning effectiveness of disease-modifying antirheumatic drugs and prednisone in the treatment of rheumatoid arthritis

Arthritis and Rheumatism

Volumn 11, Issue 5, 1998, Pages 375-380

  Wolfe, Frederick ^a,d   Albert, Daniel A ^b   Pincus, Theodore ^c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

Author keywords

Disease modifying antirheumatic drugs; Rheumatoid arthritis; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LONG TERM CARE; MAJOR CLINICAL STUDY; META ANALYSIS; RATING SCALE; RHEUMATOID ARTHRITIS; UNITED STATES;

EID: 84988305200     PISSN: 0004-3591     EISSN: 1529-0131     Source Type: Journal    
DOI: 10.1002/art.1790110508     Document Type: Article

References (32)

1. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
2. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
3. Boers M, Guyatt GH, Oxman AD. Combined effect size: comment on the metaanalysis of second-line drugs in rheumatoid arthritis [letter]. Arthritis Rheum 1991;34:1342.
4. Felson DT, Anderson JJ, Chernoff MC, Meenan RF. The comparative efficacy of cyclosporine and other second line drugs in rheumatoid arthritis: update of a metaanalysis [abstract]. Arthritis Rheum 1995;38 Suppl 9:S283.
5. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995;9:619-32.
6. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988;41:1037-41.
7. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
8. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
9. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
10. Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 1991;18:1008-14.
11. Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol 1997;15:S27-38.
12. Bellamy N, Brooks PM, Campbell J, Drane D, Dupen F. An Australian survey of current prescribing practices of methotrexate in rheumatoid arthritis. Aust N Z J Med 1994;24:214-6.
13. Katz WA. Patient selection. J Rheumatol 1990;17 Suppl 25:39-41.
14. Kay EA, Pullar T. Variations among rheumatologists in prescribing and monitoring of disease modifying antirheumatoid drugs. Br J Rheumatol 1992;31:477-83.
15. Stata Corporation. Stata statistical software: release 4.0. College Station (TX): Stata Corporation; 1995.
16. Feinstein AR. An additional basic science for clinical medicine. II. The limitations of randomized trials. Ann Intern Med 1983;99:544-50.
17. Wolfe F. The prognosis of rheumatoid arthritis: assessment of disease activity and disease severity in the clinic. Am J Med 1997;103:125-85.
18. Wolfe F. Data collection and utilization: a methodology for clinical practice and clinical research. In: Wolfe F, Pincus T, editors. Rheumatoid arthritis: pathogenesis, assessment, outcome, and treatment. New York: Marcel Dekker; 1994. p. 463-514.
19. Pincus T, Stein CM. What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observations, or clinical protocols? J Rheumatol 1995;22:1611-7.
20. Pincus T. Why should rheumatologists collect patient self-report questionnaires in routine rheumatologic care? Rheum Dis Clin North Am 1995;21:271-319.
21. Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL, et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992;35:259-69.
22. Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell AS. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. J Rheumatol 1995;22:836-43.
23. Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991;18:1290-7.
24. Wolfe F. Rheumatoid arthritis. In: Bellamy N, editor. Prognosis in the rheumatic diseases. Dordrecht: Kluwer Academic Publishers; 1991. p. 37-82.
25. Pincus T. The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin Arthritis Rheum 1992;21:2-15.
26. Wilske KR, Healey LA. Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989;16:565-7.
27. Scott DL, Coulton BL, Chapman JH, Bacon PA, Popert AJ. The long-term effects of treating rheumatoid arthritis. J R Coll Physicians Lond 1983;17:79-85.
28. Rasker JJ, Cosh JA. Long-term effects of treating rheumatoid arthritis. Baillieres Clin Rheumatol 1992;6:141-60.
29. De Asit N, Le Loet X, Czernichow P, Bertho JM, Delcambre B, Tonnel F, et al. How do French rheumatologists treat early rheumatoid arthritis? Rev Rhum Engl Ed 1996;63:185-95.
30. O'Dell JR. Combination therapy for rheumatoid arthritis: a step closer to the goal. Ann Rheum Dis 1996;55:781-3.
31. Kremer JM. The changing face of therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1995;21:845-52.
32. Kirwan JR, Chaput de Saintonge DM, Joyce CR, Holmes J, Currey HL. Inability of rheumatologists to describe their true policies for assessing rheumatoid arthritis. Ann Rheum Dis 1986;45:156-61.